Symptomatic Control of Neuroendocrine Tumors with Everolimus

被引：0
作者：
Bainbridge, H. [1 ]
Larbi, E. [2 ]
Middleton, G. [2 ]
机构：
[1] Royal Marsden Hosp, London SW3 6JJ, England
[2] Royal Surrey Cty Hosp, Guildford, Surrey, England
来源：
NEUROENDOCRINOLOGY | 2012年 / 96卷
关键词：
neuroendocrine; carcinoid; everolimus; symptom;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：18 / 18
页数：1
相关论文
共 50 条
  • [31] Everolimus and sunitinib: from mouse models to treatment of pancreatic neuroendocrine tumors
    Liakakos, Theodore
    Roukos, Dimitrios H.
    FUTURE ONCOLOGY, 2011, 7 (09) : 1025 - 1029
  • [32] Efficacy and Safety of Everolimus plus Somatostatin Analogues in Patients with Neuroendocrine Tumors
    Ge, Wenhao
    Zhou, Dongkai
    Zhu, Lijun
    Song, Wei
    Wang, Weilin
    JOURNAL OF CANCER, 2018, 9 (24): : 4783 - 4790
  • [33] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Chan, Jennifer A.
    Mayer, Robert J.
    Jackson, Nadine
    Malinowski, Paige
    Regan, Eileen
    Kulke, Matthew H.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 71 (05) : 1241 - 1246
  • [34] Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors
    Jennifer A. Chan
    Robert J. Mayer
    Nadine Jackson
    Paige Malinowski
    Eileen Regan
    Matthew H. Kulke
    Cancer Chemotherapy and Pharmacology, 2013, 71 : 1241 - 1246
  • [35] Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
    Cella, C. A.
    Barberis, M.
    Spada, F.
    Pisa, E.
    Laffi, A.
    Gritti, S.
    Leone, I
    Zanetti, C.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2018, 106 : 4 - 4
  • [36] Efficacy of Everolimus Combined with 177Lu-Dotatate in the Treatment of Neuroendocrine Tumors
    Aljubran, Ali
    Badran, Ahmed
    Alrowaily, Mohamed
    Raef, Hussein
    Alzahrani, Ahmed M.
    Almuhaideb, Ahmed
    Almanea, Hadeel
    El-Dali, Abdelmoneim
    Tuli, Mahmoud
    Bazarbashi, Shouki
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2024, 39 (02) : 164 - 168
  • [37] Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
    Benslama, Noura
    Bollard, Julien
    Vercherat, Cecile
    Massoma, Patrick
    Roche, Colette
    Hervieu, Valerie
    Peron, Julien
    Lombard-Bohas, Catherine
    Scoazec, Jean-Yves
    Walter, Thomas
    INVESTIGATIONAL NEW DRUGS, 2016, 34 (05) : 654 - 662
  • [38] Angiogenic Circulating Biomarkers in Patients with Advanced Pancreatic Neuroendocrine Tumors Treated with Everolimus
    Cella, C. A.
    Spada, F.
    Labanca, V
    Radice, D.
    Rubino, M.
    Zorzino, L.
    Fazio, N.
    NEUROENDOCRINOLOGY, 2017, 105 : 3 - 3
  • [39] Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors
    Noura Benslama
    Julien Bollard
    Cécile Vercherat
    Patrick Massoma
    Colette Roche
    Valérie Hervieu
    Julien Peron
    Catherine Lombard-Bohas
    Jean-Yves Scoazec
    Thomas Walter
    Investigational New Drugs, 2016, 34 : 654 - 662
  • [40] Clinical Impact of Everolimus Cumulative Dose on Pancreatic Neuroendocrine Tumors (pNETs) Outcome
    Berardi, R.
    Torniai, M.
    Onofri, A.
    Partelli, S.
    Guglielmi, S.
    Gucciardino, C.
    Savini, A.
    Ferretti, B.
    Enrica, T.
    Giustini, L.
    Falconi, M.
    Cascinu, S.
    NEUROENDOCRINOLOGY, 2014, 99 (3-4) : 275 - 275
12345